Checkmate 067 - combined nivolumab and ipilimumab
12 Apr 2017
Checkmate 067 - combined nivolumab and ipilimumab
Durable responses to avelumab in patients with Merkel cell carcinoma
Understanding response and resistance to cancer therapy: Lessons learned from melanoma
Conference goals and cancer care in Brazil
Head and neck melanoma
Positive impact of specialised surgery in the fight against cancer
Advances in malignant melanoma
Editor's ESMO 2016 roundup
ESMO 2016 conference highlights
Comment: Ipilimumab in high risk stage III melanoma
Comment: Ribociclib for breast cancer
Highlights of ESMO 2016